Cargando…

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells

Combinations of gemcitabine and trabectedin exert modest synergistic cytotoxic effects on two pancreatic cancer cell lines. Here, systems pharmacodynamic (PD) models that integrate cellular response data and extend a prototype model framework were developed to characterize dynamic changes in cell cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Xin, Koch, Gilbert, Ait-Oudhia, Sihem, Straubinger, Robert M., Jusko, William J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108803/ https://www.ncbi.nlm.nih.gov/pubmed/27895579 http://dx.doi.org/10.3389/fphar.2016.00421

Ejemplares similares

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach
por: Mody, Hardik, et al.
Publicado: (2023)

Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
por: Ande, Anusha, et al.
Publicado: (2018)

In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization
por: Mody, Hardik, et al.
Publicado: (2023)

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin
por: Mody, Hardik, et al.
Publicado: (2022)

The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Determination of Extravasation Effects of Nal-Iri and Trabectedin and Evaluation of Treatment Options for Trabectedin Extravasation in a Preclinical Animal Model
por: Keritam, Omar, et al.
Publicado: (2022)

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
por: Fleisher, Brett, et al.
Publicado: (2021)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
por: Fleisher, Brett, et al.
Publicado: (2017)

Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer
por: Lin, Qingxiang, et al.
Publicado: (2022)

Chloroquine sensitizes MDA-MB-231 cells to osimertinib through autophagy–apoptosis crosstalk pathway
por: Fleisher, Brett, et al.
Publicado: (2019)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
por: Lin, Lanke, et al.
Publicado: (2023)

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2023)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy
por: Liew, Hui Shan, et al.
Publicado: (2022)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
por: Yao, Jingjing, et al.
Publicado: (2022)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of the Combination of Rhein and Curcumin in the Treatment of Chronic Kidney Disease in Rats
por: He, Xiaoying, et al.
Publicado: (2020)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
por: Xiao, Zhijun, et al.
Publicado: (2021)

Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α
por: Zhao, Zhanxue, et al.
Publicado: (2023)

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
por: O'Reilly, Eileen M., et al.
Publicado: (2017)

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
por: Ávila-Arroyo, Sonia, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
por: Koch-Heier, Julia, et al.
Publicado: (2022)

Safely combining trabectedin with radiotherapy to treat myxoid liposarcoma
por: Chen, Mark, et al.
Publicado: (2019)

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
por: Kamta, Jeff, et al.
Publicado: (2017)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
por: Kasper, Bernd, et al.
Publicado: (2015)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
por: He, Hua, et al.
Publicado: (2022)

Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
por: Wooten, David J., et al.
Publicado: (2022)

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines
por: Ragone, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9lson12nsgqcg7pcjgqmne2gug